* Qualified Vero Master Cell Bank and Working Cell Bank, originating from WHO banks, are available for purchase, licensing, and use in Intravacc-led CDMO programs * Intravacc has used its Vero cell line for viral vaccine development since 1987, supporting oncolytic, live-attenuated, inactivated, and vector vaccine programs * Integrated process development, analytics, cGMP manufacturing, quality control, and technology transfer help partners reduce CMC risk and move viral vaccine candidates...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by cGMP manufacturing
PSD Bank Rhein-Ruhr eG
The 2025-2027 approval helps French innovators access Intravacc's vaccine development, analytical development and cGMP manufacturing services * French Ministry approval recognizes Intravacc as a private research organization for CIR-related R&D expenses for 2025, 2026 and 2027. * French biotech and pharmaceutical partners may declare qualifying R&D operations outsourced to Intravacc under the CIR framework, subject to project-level eligibility and applicable rules.
Biologics Outsourcing Market Report 2024-2031 | Industry Growth, Key Players & Forecast
The Biologics Outsourcing Market is rapidly growing, driven by increasing demand for biopharmaceuticals and cost-effective manufacturing solutions globally.
Biologics Outsourcing Market Report 2024-2031
AUSTIN, TX, UNITED STATES, May 28, 2025 / EINPresswire.com/ -- Biologics Outsourcing Market Value and Growth Outlook The Biologics Outsourcing Market Size was projected to grow at a compound annual growth rate (CAGR) between 2024 and 2031. North America North America continues to dominate the biologics outsourcing space, driven by a robust pharmaceutical industry, early adoption of biologics, and significant R&D spending.
AsiaNet - View Release
Ajinomoto Bio-Pharma Services Awarded Three 'CDMO Leadership Awards' Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received three CDMO Leadership Awards in the categories Capabilities, Compatibility, and Expertise in both the Overall and Big Pharma respondent groups.
AsiaNet - View Release
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity.
AsiaNet - View Release
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP(R), Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs.
AsiaNet - View Release
First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services' AJIPHASE Technology Receives FDA Approval TOKYO, Oct. 7, 2020 /PRNewswire-AsiaNet/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the US FDA has approved the first commercial drug manufactured via Aji Bio-Pharma's proprietary AJIPHASE(R) production process.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with cGMP
Contact cGMP, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack